Verrica Pharmaceuticals (VRCA) Issues Quarterly Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) announced its quarterly earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.03), Fidelity Earnings reports.

Verrica Pharmaceuticals stock traded down $0.84 during mid-day trading on Thursday, hitting $12.50. The company had a trading volume of 620 shares, compared to its average volume of 36,418. Verrica Pharmaceuticals has a 1 year low of $12.01 and a 1 year high of $23.29.

Separately, Zacks Investment Research lowered shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 20th.

In other news, COO Linda Palczuk acquired 2,500 shares of the firm’s stock in a transaction dated Monday, September 17th. The stock was acquired at an average cost of $16.52 per share, with a total value of $41,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul B. Manning acquired 33,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The stock was purchased at an average cost of $15.08 per share, with a total value of $497,640.00. The disclosure for this purchase can be found here. Insiders bought 38,305 shares of company stock valued at $583,151 over the last three months.

TRADEMARK VIOLATION WARNING: “Verrica Pharmaceuticals (VRCA) Issues Quarterly Earnings Results” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.wkrb13.com/2018/11/08/verrica-pharmaceuticals-vrca-issues-quarterly-earnings-results.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Featured Story: Capital Gains

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply